TITLE:
A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) in Combination With Ribavirin in Patients With Chronic Hepatitis C (CHC) Previously Treated With PEG-Intron + Ribavirin

CONDITION:
Hepatitis C, Chronic

INTERVENTION:
Ribavirin

SUMMARY:

      This study will evaluate the efficacy, safety and tolerability of PEGASYS plus ribavirin in
      patients with CHC who could not tolerate or were not responsive to 12 weeks of therapy with
      PEG-Intron plus ribavirin. The anticipated time on study treatment is 1-2 years, and the
      target sample size is >100 individuals.
    

DETAILED DESCRIPTION:
NONE

ELIGIBILITY:
Gender: All
Age: 18 Years to N/A
Criteria:

        Inclusion Criteria:

          -  adult patients at least 18 years of age

          -  CHC infection, genotype 1

          -  unable to tolerate or not responsive to PEG-Intron + ribavirin therapy after 12 weeks
             of treatment

          -  use of 2 forms of contraception during the study in both men and women

        Exclusion Criteria:

          -  women who are pregnant or breast-feeding

          -  medical condition associated with chronic liver disease (eg, hemochromatosis,
             autoimmune hepatitis, alcoholic liver disease, toxin exposures)

          -  patients with decompensated cirrhosis

          -  patients receiving any systemic antiviral therapy or investigational drug, other than
             PEG-Intron + ribavirin, 24 weeks prior to the first dose of study drug
      
